CRVS vs. KLAC
CRVS (Corvus Pharmaceuticals, Inc.) and KLAC (KLA Corporation) are both stocks. CRVS operates in Biotechnology (Healthcare), while KLAC operates in Semiconductor Equipment & Materials (Technology). Over the past 10 years, CRVS returned -1.93%/yr vs 42.51%/yr for KLAC. At a 0.18 correlation, their price movements are largely independent.
Performance
CRVS vs. KLAC - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRVS achieves a 52.21% return, which is significantly lower than KLAC's 75.84% return. Over the past 10 years, CRVS has underperformed KLAC with an annualized return of -1.93%, while KLAC has yielded a comparatively higher 42.51% annualized return.
CRVS
- 1D
- 1.03%
- 1M
- -25.35%
- YTD
- 52.21%
- 6M
- 33.03%
- 1Y
- 212.53%
- 3Y*
- 52.88%
- 5Y*
- 34.23%
- 10Y*
- -1.93%
KLAC
- 1D
- 0.28%
- 1M
- 23.14%
- YTD
- 75.84%
- 6M
- 76.86%
- 1Y
- 174.24%
- 3Y*
- 68.36%
- 5Y*
- 47.88%
- 10Y*
- 42.51%
CRVS vs. KLAC - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CRVS Corvus Pharmaceuticals, Inc. | 52.21% | 43.93% | 203.98% | 107.06% | -64.73% | -32.30% | -34.56% | 48.23% | -64.58% | -27.55% |
KLAC KLA Corporation | 75.84% | 94.48% | 9.36% | 56.05% | -11.20% | 68.05% | 47.94% | 103.99% | -12.49% | 36.80% |
Correlation
The correlation between CRVS and KLAC is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Mar 24, 2016 | 0.18 |
Fundamentals
CRVS:
$1.05B
KLAC:
$281.46B
CRVS:
-$0.53
KLAC:
$35.29
CRVS:
4.38
KLAC:
48.27
CRVS:
$0.00
KLAC:
$13.10B
CRVS:
-$26.00K
KLAC:
$8.09B
CRVS:
-$47.43M
KLAC:
$5.77B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRVS vs. KLAC — Risk / Return Rank
CRVS
KLAC
CRVS vs. KLAC - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Corvus Pharmaceuticals, Inc. (CRVS) and KLA Corporation (KLAC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CRVS | KLAC | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.65 | ||
| Sortino ratioReturn per unit of downside risk | +0.82 | ||
| Omega ratioGain probability vs. loss probability | 1.51 | 1.53 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 3.89 | 7.83 | -3.93 |
| Martin ratioReturn relative to average drawdown | 8.69 | 24.98 | -16.28 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CRVS | KLAC | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.18 | 3.83 | -2.65 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.26 | 1.12 | -0.86 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.02 | 1.03 | -1.05 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.02 | 0.45 | -0.47 |
Drawdowns
CRVS vs. KLAC - Drawdown Comparison
The maximum CRVS drawdown since its inception was -96.97%, which is greater than KLAC's maximum drawdown of -83.74%. Use the drawdown chart below to compare losses from any high point for CRVS and KLAC.
Loading charts...
Drawdown Indicators
| CRVS | KLAC | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.97% | -83.74% | -13.23% |
Max Drawdown (1Y)Largest decline over 1 year | -54.94% | -22.41% | -32.53% |
Max Drawdown (3Y)Largest decline over 3 years | -72.02% | -34.95% | -37.07% |
Max Drawdown (5Y)Largest decline over 5 years | -92.40% | -40.28% | -52.12% |
Max Drawdown (10Y)Largest decline over 10 years | -96.97% | -40.28% | -56.69% |
Current DrawdownCurrent decline from peak | -54.08% | 0.00% | -54.08% |
Average DrawdownAverage peak-to-trough decline | -69.33% | -29.34% | -39.99% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.56% | 7.01% | +17.55% |
Volatility
CRVS vs. KLAC - Volatility Comparison
Corvus Pharmaceuticals, Inc. (CRVS) has a higher volatility of 23.73% compared to KLA Corporation (KLAC) at 15.00%. This indicates that CRVS's price experiences larger fluctuations and is considered to be riskier than KLAC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRVS | KLAC | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.73% | 15.00% | +8.73% |
Volatility (6M)Calculated over the trailing 6-month period | 111.90% | 37.77% | +74.13% |
Volatility (1Y)Calculated over the trailing 1-year period | 180.94% | 45.78% | +135.16% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 131.04% | 43.06% | +87.98% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 111.13% | 41.42% | +69.71% |
Dividends
CRVS vs. KLAC - Dividend Comparison
CRVS has not paid dividends to shareholders, while KLAC's dividend yield for the trailing twelve months is around 0.38%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CRVS Corvus Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
KLAC KLA Corporation | 0.38% | 0.61% | 0.96% | 0.92% | 1.25% | 0.91% | 1.35% | 1.74% | 3.17% | 2.15% | 2.67% | 2.94% |
Financials
CRVS vs. KLAC - Financials Comparison
This section allows you to compare key financial metrics between Corvus Pharmaceuticals, Inc. and KLA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CRVS and KLAC have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRVS has higher volatility (23.73%) compared to KLAC (15.00%). In terms of maximum drawdown, CRVS dropped -96.97% vs KLAC's -83.74%.
KLAC currently has the higher Sharpe Ratio (3.83 vs 1.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRVS and KLAC
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer